Log in to your Inderes Free account to see all free content on this page.
Cantargia
1.715
SEK
-7.25 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,312 following
-7.25%
-5.35%
-50.97%
-61.96%
-54.12%
-55.78%
-89.04%
-89.61%
-75.73%
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Read moreMarket cap
472.53M SEK
Turnover
2.48M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
21.2.
2025
Annual report '24
13.5.
2025
Interim report Q1'25
15.5.
2025
General meeting '24
ShowingAll content types
Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer
Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio